PD48-06 2 YEAR CLINICAL AND IMMUNOLOGIC OUTCOMES OF INTRADERMAL BCG PRIMING PRIOR TO INTRAVESICAL INDUCTION IMMUNOTHERAPY FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER
Authors:
- 1 April 2017
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e902-e903